Library · Metabolic & weight · Adjunct to insulin therapy for type 1 and type 2 diabetes.
Pramlintide
Symlin, AC137, Tripro-amylin
A synthetic amylin analogue, marketed as Symlin and FDA-approved in 2005 as an add-on to insulin for type 1 and type 2 diabetes. It slows gastric emptying, curbs post-meal glucagon, and boosts satiety, and remains the only approved drug in its class.
Research score 95/100. Reference only, not a dose.
- Blood Sugar Control
- Appetite Suppression
- Metabolic Enhancement
- Gut Health
- Insulin Regulation
- US status
- Prescription Only
- Approval
- FDA Approved
- Evidence
- Extensive Human Studies
- Research score
- 95 / 100
- Indication
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (as adjunct to insulin).
- Origin
- USA
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Binds amylin receptors in the brainstem and hypothalamus to slow stomach emptying and cut glucagon secretion via calcitonin-receptor pathways, working alongside insulin to limit liver glucose output and enhance satiety through area postrema and vagal signaling.
Safety file
Notable risk of severe hypoglycemia with insulin, requiring dose adjustment; avoided in gastroparesis, hypoglycemia unawareness, or high HbA1c; nausea, vomiting, appetite loss, fatigue, headache, and dizziness are common.
- Nausea
- Vomiting
- Anorexia
- Fatigue
- Headache
- Dizziness
- Hypoglycemia
- Injection site reactions